http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100805269-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-80 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-39 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 |
| filingDate | 2005-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2008-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2008-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-100805269-B1 |
| titleOfInvention | Antithrombotic Agents Including Disintegrin-like Domain |
| abstract | The present invention performed cloning and expression of human ADAM15 disintegrin-like domains and derivatives thereof to investigate integrin binding specificity as well as antiplatelet activity. Yeast expressing ADAM15 disintegrin-like domains could inhibit αIIbβ3 binding to its ligand in a dose dependent form. In particular, mutation of the RPT RGD sequence to NWK RGD in the disintegrin-like domain increased its binding specificity for integrin αIIbβ3. NWK mutants also reduced integrin αIIbβ3 activation, indicating improved human platelet aggregation inhibition compared to the original ADAM15 disintegrin-like domain. Therefore, the protein of the present invention can be used as an antithrombotic agent in cardiovascular disease. |
| priorityDate | 2005-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 72.